Citation: Yonghui Sun, Xin Luo, Zimo Yang, Wenxing Lv, Lixia Chen, Hua Li, Yu Rao. Developing potent BTK^C481S PROTACs for ibrutinib-resistant malignant lymphoma[J]. Chinese Chemical Letters, ;2023, 34(6): 107924. doi: 10.1016/j.cclet.2022.107924 shu

Developing potent BTK^C481S PROTACs for ibrutinib-resistant malignant lymphoma

Yonghui Sun ^{a, 1} ,
Xin Luo ^{b, 1} ,
Zimo Yang ^a ,
Wenxing Lv ^a ,
Lixia Chen ^b ,
Hua Li ^{b, c, *,} ,
Yu Rao ^{a, *,}

a.
MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, China
b.
Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang, 110016, China
c.
Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China

li_hua@hust.edu.cn

yrao@tsinghua.edu.cn

Received Date: 1 May 2022
Revised Date: 17 October 2022
Accepted Date: 18 October 2022
Available Online: 20 October 2022

Figures(6)

Ibrutinib is a first-line treatment drug for B-cell malignancies. However, resistance to ibrutinib has been reported due to BTK^C481S mutation. Although PROTAC strategy is expected to overcome this clinical resistance, it has limitations such as large molecular weight and moderate bioactivity, which restrict its potential clinical application. Herein, we report a new type of potent BTK^C481S-targeting PROTAC degrader. Through design, computer-assisted optimization and SAR studies, we have developed a representative BTK^C481S degrader L6 with a much smaller molecular weight and improved solubility. Notably, L6 demonstrates better BTK degrading activity and lower IC₅₀ value in ibrutinib-resistant cell line than the first-generation BTK degrader P13I. Optimization strategy of L6 provides a general approach in the development of PROTACs targeting BTK and other proteins for future study.
- Drug design,
- Ibrutinib resistance,
- BTK degraders,
- PROTACs,
- B-cell lymphoma
1. [1]
  B.D. Cheson, J.P. Leonard, N. Engl. J. Med. 359 (2008) 613-626. doi: 10.1056/NEJMra0708875
2. [2]
  L. Pasqualucci, D. Dominguez-Sola, A. Chiarenza, et al., Nature 471 (2011) 189-195. doi: 10.1038/nature09730
3. [3]
  L.M. Morton, S.S. Wang, S.S. Devesa, et al., Blood 107 (2006) 265-276. doi: 10.1182/blood-2005-06-2508
4. [4]
  J.C. Byrd, R.R. Furman, S.E. Coutre, et al., N. Engl. J. Med. 369 (2013) 32-42. doi: 10.1056/NEJMoa1215637
5. [5]
  J.A. Burger, A. Wiestner, Nat. Rev. Cancer 18 (2018) 148-167. doi: 10.1038/nrc.2017.121
6. [6]
  L.A. Honigberg, A.M. Smitha, M. Sirisawada, et al., Proc. Natl. Acad. Sci. U. S. A. 107 (2010) 13075-13080. doi: 10.1073/pnas.1004594107
7. [7]
  W.H. Wilson, R.M. Young, R. Schmitz, et al., Nat. Med. 21 (2015) 922-926. doi: 10.1038/nm.3884
8. [8]
  G. Li, X. Liu, X. Chen, Nat. Rev. Clin. Oncol. 17 (2020) 589-590. doi: 10.1038/s41571-020-0414-y
9. [9]
  J.A. Woyach, R.R. Furman, T. Liu, et al., N. Engl. J. Med. 370 (2014) 2286-2294. doi: 10.1056/NEJMoa1400029
10. [10]
  R.R. Furman, S. Cheng, P. Lu, et al., N. Engl. J. Med. 370 (2014) 2352-2354. doi: 10.1056/NEJMc1402716
11. [11]
  K.M. Sakamoto, K.B. Kim, A. Kumagai, et al., Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 8554-8559. doi: 10.1073/pnas.141230798
12. [12]
  G.E. Winter, D.L. Buckley, J. Paulk, et al., Science 348 (2015) 1376-1381. doi: 10.1126/science.aab1433
13. [13]
  A. Mullard, Nat. Rev. Drug Discov. 17 (2018) 777.
14. [14]
  X. Li, Y. Song, J. Hematol. Oncol. 13 (2020) 50. doi: 10.1002/jeq2.20016
15. [15]
  Y. Sun, X. Zhao, N. Ding, et al., Cell Res. 28 (2018) 779-781. doi: 10.1038/s41422-018-0055-1
16. [16]
  Y. Sun, N. Ding, Y. Song, et al., Leukemia 33 (2019) 2105-2110. doi: 10.1038/s41375-019-0440-x
17. [17]
  R.E. Davis, V.N. Ngo, G. Lenz, et al., Nature 463 (2010) 88-92. doi: 10.1038/nature08638
1. [1]
  Yang Liu , Jing Liang , Mengzhu Zheng , Haoze Song , Lixia Chen , Hua Li . PD-L1/SHP2 dual PROTACs inhibit melanoma by enhancing T-cell killing activity. Chinese Chemical Letters, 2025, 36(6): 110317-. doi: 10.1016/j.cclet.2024.110317
2. [2]
  Yang Liu , Yan Liu , Kaiyin Yang , Zhiruo Zhang , Wenbo Zhang , Bingyou Yang , Hua Li , Lixia Chen . A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2. Chinese Chemical Letters, 2024, 35(8): 109264-. doi: 10.1016/j.cclet.2023.109264
3. [3]
  Bairu Meng , Zongji Zhuo , Han Yu , Sining Tao , Zixuan Chen , Erik De Clercq , Christophe Pannecouque , Dongwei Kang , Peng Zhan , Xinyong Liu . Design, synthesis, and biological evaluation of benzo[4,5]thieno[2,3-d]pyrimidine derivatives as novel HIV-1 NNRTIs. Chinese Chemical Letters, 2024, 35(6): 108827-. doi: 10.1016/j.cclet.2023.108827
4. [4]
  Han Yuan , Fengcai Zhang , Hongzhe Huang , Jiafei Wu , Yi Yang , Wanyi Huang , Dongjing Yang , Zhuoming Li , Zhe Li , Ling Huang , Yi-You Huang , Hai-Bin Luo , Lei Guo . Discovery of 3-trifluoromethyl-substituted pyrazoles as selective phosphodiesterase 10A inhibitors for orally attenuating isoprenaline-induced cardiac hypertrophy. Chinese Chemical Letters, 2025, 36(4): 109965-. doi: 10.1016/j.cclet.2024.109965
5. [5]
  Shaoqing Du , Xinyong Liu , Xueping Hu , Peng Zhan . Targeting novel sites represents an effective strategy for combating drug resistance. Chinese Chemical Letters, 2025, 36(1): 110378-. doi: 10.1016/j.cclet.2024.110378
6. [6]
  Liping Zhao , Xixi Guo , Zhimeng Zhang , Xi Lu , Qingxuan Zeng , Tianyun Fan , Xintong Zhang , Fenbei Chen , Mengyi Xu , Min Yuan , Zhenjun Li , Jiandong Jiang , Jing Pang , Xuefu You , Yanxiang Wang , Danqing Song . Novel berberine derivatives as adjuvants in the battle against Acinetobacter baumannii: A promising strategy for combating multi-drug resistance. Chinese Chemical Letters, 2024, 35(10): 109506-. doi: 10.1016/j.cclet.2024.109506
7. [7]
  Jiechen Liu , Xiaoguang Li , Ruiyang Xia , Yuqi Wang , Fenghe Zhang , Yongzhi Pang , Qing Li . Efficient suppression of oral squamous cell carcinoma through spatial dimension conversion drug delivery systems-enabled immunomodulatory-photodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109619-. doi: 10.1016/j.cclet.2024.109619
8. [8]
  Zimo Yang , Yan Tong , Yongbo Liu , Qianlong Liu , Zhihao Ni , Yuna He , Yu Rao . Developing selective PI3K degraders to modulate both kinase and non-kinase functions. Chinese Chemical Letters, 2024, 35(11): 109577-. doi: 10.1016/j.cclet.2024.109577
9. [9]
  Yong-Dan Zhao , Yidan Wang , Rongrong Wang , Lina Chen , Hengtong Zuo , Xi Wang , Jihong Qiang , Geng Wang , Qingxia Li , Canqi Ping , Shuqiu Zhang , Hao Wang . Reversing artemisinin resistance by leveraging thermo-responsive nanoplatform to downregulating GSH. Chinese Chemical Letters, 2024, 35(6): 108929-. doi: 10.1016/j.cclet.2023.108929
10. [10]
  Yixuan Wang , Jiexin Li , Zhihao Shang , Chengcheng Feng , Jianmin Gu , Maosheng Ye , Ran Zhao , Danna Liu , Jingxin Meng , Shutao Wang . Wettability-driven synergistic resistance of scale and oil on robust superamphiphobic coating. Chinese Chemical Letters, 2024, 35(7): 109623-. doi: 10.1016/j.cclet.2024.109623
11. [11]
  Yuxin Li , Chengbin Liu , Qiuju Li , Shun Mao . Fluorescence analysis of antibiotics and antibiotic-resistance genes in the environment: A mini review. Chinese Chemical Letters, 2024, 35(10): 109541-. doi: 10.1016/j.cclet.2024.109541
12. [12]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
13. [13]
  Linghui Zou , Meng Cheng , Kaili Hu , Jianfang Feng , Liangxing Tu . Vesicular drug delivery systems for oral absorption enhancement. Chinese Chemical Letters, 2024, 35(7): 109129-. doi: 10.1016/j.cclet.2023.109129
14. [14]
  Fengjie Liu , Fansu Meng , Zhenjiang Yang , Huan Wang , Yuehong Ren , Yu Cai , Xingwang Zhang . Exosome-biomimetic nanocarriers for oral drug delivery. Chinese Chemical Letters, 2024, 35(9): 109335-. doi: 10.1016/j.cclet.2023.109335
15. [15]
  Haiyang Peng , Zhipeng Xie , Shuiqing Lu , Da Zhang , Bin Yang , Feng Liang . Dual-functionality composites of polyaniline-coated oxidized carbon nanohorns: Efficient wave absorption and enhanced corrosion resistance. Chinese Chemical Letters, 2025, 36(6): 110818-. doi: 10.1016/j.cclet.2025.110818
16. [16]
  Chunshi He , Linqing Li , Yuanrong Sun , Xuefang Wang , Jie Ren , Jianbo Li . Enhanced durability of a novel thiol-epoxy network thermosets with excellent hygrothermal and chemical resistance. Chinese Chemical Letters, 2025, 36(6): 110905-. doi: 10.1016/j.cclet.2025.110905
17. [17]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
18. [18]
  Qijie Gong , Jian Song , Yihui Song , Kai Tang , Panpan Yang , Xiao Wang , Min Zhao , Liang Ouyang , Li Rao , Bin Yu , Peng Zhan , Saiyang Zhang , Xiaojin Zhang . New techniques and strategies in drug discovery (2020–2024 update). Chinese Chemical Letters, 2025, 36(3): 110456-. doi: 10.1016/j.cclet.2024.110456
19. [19]
  Bharathi Natarajan , Palanisamy Kannan , Longhua Guo . Metallic nanoparticles for visual sensing: Design, mechanism, and application. Chinese Journal of Structural Chemistry, 2024, 43(9): 100349-100349. doi: 10.1016/j.cjsc.2024.100349
20. [20]
  Shengdong Sun , Cheng Wang , Shikuo Li . Interfacial channel design on the charge migration for photoelectrochemical applications. Chinese Journal of Structural Chemistry, 2024, 43(12): 100398-100398. doi: 10.1016/j.cjsc.2024.100398

Get Citation

PDF

XML

Metrics

PDF Downloads(5)
Abstract views(735)
HTML views(38)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Developing potent BTKC481S PROTACs for ibrutinib-resistant malignant lymphoma

Metrics

通讯作者: 陈斌, bchen63@163.com

Developing potent BTK^C481S PROTACs for ibrutinib-resistant malignant lymphoma